aaaaa
aaaaa
aaaaa
Sagimet Biosciences to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference and Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN MATEO, Calif., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional…
aaaaa
Pharma Company Gets FDA Green Light For Next Phase Trial For Tourette Syndrome
SciSparc Ltd.(NASDAQ:SPRC), a clinical-stage pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has approved its investigational new drug (IND), which enables the company to proceed to Phase…
aaaaa
Clinical Decision Support Platform Market to Reach $2.4 Billion, Globally, by 2033 at 7.3% CAGR: Allied Market Research
Wilmington, Delaware, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Allied Market Research published a report, titled, "Clinical Decision Support Platform Market by Component (Software and Services), Delivery Mode (On-Premises…
aaaaa
aaaaa
Kura Oncology Announces Publication of Ziftomenib Phase 1 Results in The Lancet Oncology
SAN DIEGO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of…
aaaaa
Hurricane Helene Shutters Baxter International's Key Manufacturing Hub In North Carolina
Baxter International Inc (NYSE:BAX). has shut down its largest manufacturing facility following significant damage caused by Hurricane Helene. The hurricane, which hit the Southeast of the U.S. with deadly force,…
aaaaa
aaaaa
Yomi Robotic Dental Implant System Drives Increased Implant Volume and Practice Profitability According to Growth Study
Dental Economics publishes study by leading Missouri dentist Dr. Jonathan Ehlers on how dental practices are increasing implant volume, efficiency, and profitability by offering robot-guided implant placement. MIAMI, Sept. 30,…
aaaaa
Sanofi, Regeneron's Dupixent Gets FDA Approval For COPD
Sanofi (NASDAQ: SNY) and partner Regeneron (NASDAQ: REGN) announced that the FDA has approved their blockbuster drug, Dupixent, for its sixth indication — chronic obstructive pulmonary disease (COPD) — in the United…
aaaaa
aaaaa
Umoja Biopharma Announces Oral Presentation at the American College of Rheumatology Convergence 2024
SEATTLE, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc. (Umoja), a transformative immunotherapy company creating off-the-shelf treatments that aim to extend the reach and effectiveness of CAR-T…
aaaaa
Vaxart Announces Initiation of Sentinel Cohort for Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate
— 400 subject sentinel portion of Phase 2b study will evaluate the safety, immunogenicity and efficacy of Vaxart's next generation oral pill COVID-19 vaccine compared to an approved mRNA vaccine…
aaaaa
Gritstone bio Announces Interim Phase 2 Data for GRANITE Individualized Neoantigen Targeting Immunotherapy in Frontline Metastatic Microsatellite Stable Colorectal Cancer
--Encouraging progression-free survival data in overall population; continued follow-up needed to allow data to mature further, especially in low ctDNA subgroup where events accrue more slowly --21% relative risk reduction of…
aaaaa
Acumen Pharmaceuticals to Participate in the Bank of America CNS Therapeutics Virtual Conference
NEWTON, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for…
aaaaa
Texas Mutual Insurance and TAMACC Promote Workplace Office Safety to Improve Your Bottom Line
BUDA, Texas, Sept. 30, 2024 (GLOBE NEWSWIRE) -- A safe business not only saves you money but ensures your employees remain productive, healthy, and even more motivated. Implementing…
aaaaa
Roche Fast-Tracks Obesity Drug Development, Eyes Over $3B Sales Potential
At its Pharma Day, Swiss pharmaceutical giant Roche Holdings AG (OTC:RHHBY) outlined five priority therapeutic areas: neurology, oncology and hematology, immunology, ophthalmology, and cardiovascular, renal, and metabolism diseases. The company shared…
aaaaa
Mifepristone and Misoprostol are Not "Controlled Dangerous Substances": The American College of Medical Toxicology Issues Position Statement
Phoenix, AZ, Sept. 30, 2024 (GLOBE NEWSWIRE) -- In May of 2024, Louisiana enacted a law classifying mifepristone and misoprostol as Schedule IV controlled dangerous substances, akin to…
aaaaa
Arcturus Therapeutics/CSL Partnered COVID-19 Vaccine Surpasses Pfizer's Comirnaty Shot, Even At Lower Doses
CSL Limited (OTC:CSLLY) and Arcturus Therapeutics (NASDAQ:ARCT) announced the results of a Phase 3 head-to-head study of ARCT-154, a self-amplifying (sa-mRNA) COVID-19 vaccine, compared to Pfizer Inc’s (NYSE:PFE) shot Comirnaty. The study showed…
aaaaa
Penn Medicine, Rockefeller Neuroscience Institute and Precision Neuroscience Unveil Breakthrough Neural Implant Data at the 2024 Congress of Neurological Surgeons Annual Meeting
NEW YORK, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Today, researchers from the Perelman School of Medicine at the University of Pennsylvania (Penn Medicine) and West Virginia University's Rockefeller…
aaaaa
Johnson & Johnson/ Legend Biotech Partnered Blood Cancer Drug Extends Overall Survival, Support Use In Previously Treated Patients
Friday, Legend Biotech Corporation (NASDAQ:LEGN) and Johnson & Johnson (NYSE:JNJ) announced late-breaking three-year follow-up data from the Phase 3 CARTITUDE-4 study. Data shows that a single infusion of Carvykti (ciltacabtagene autoleucel) significantly extended overall…
aaaaa
Cytel Launches East Horizon™ Platform: Advancing the Science of Adaptive Clinical Trial Design and Simulation
Cambridge, MA, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Cytel, a leader in statistical software and advanced quantitative solutions for clinical research, announces the release of East Horizon™, an…
aaaaa
Cytokinetics Presents Additional Data From SEQUOIA-HCM at the HFSA Annual Scientific Meeting
Responder Analyses Show Treatment with Aficamten Demonstrated Improvements on Multiple Assessments of Clinical Significance to Cardiologists Results Simultaneously Published in the Journal of the American College of Cardiology SOUTH SAN FRANCISCO,…
aaaaa
Prime Medicine Inks Cell Therapy Pact With Bristol Myers Squibb Worth Over $3.5B, Streamlines Pipeline
On Monday, Prime Medicine Inc. (NASDAQ:PRME) announced a strategic research collaboration and license agreement with Bristol Myers Squibb & Co (NYSE:BMY) to develop reagents for the next generation of ex vivo T-cell therapies. Under…
aaaaa
Microbot Medical Accelerates Patient Enrollment of its Pivotal Human Clinical Trial; Expects to Complete the Trial Earlier Than Anticipated as 80% of Patients Have Completed Follow up
Confirms the Company on Track for FDA 510(k) Submission by end of 2024 Completes All IDE required Tests and Receives Final IDE Approval from the FDA for the ACCESS-PVI Study BRAINTREE,…
aaaaa
aaaaa
IGI Announces CRADA with National Cancer Institute to Test Proprietary Oral Cbl/b Inhibitor Treatment in Triple Negative Breast Cancer
Casitas B-lineage lymphoma b (Cbl/b) is an E3 ubiquitin ligase that has been shown to be a key regulator of the activation of T and natural killer (NK) cells in…
aaaaa
COUR Pharmaceuticals Announces Positive Top-line Results from Phase 2a Study of CNP-104 in Primary Biliary Cholangitis
CNP-104 demonstrated potential efficacy across multiple immunological and clinical measurements, supporting its continued development as the first disease-modifying treatment for Primary Biliary Cholangitis CNP-104 was safe and well-tolerated, meeting all primary…
aaaaa
Madrigal Pharmaceuticals Announces Publication of Positive Health-Related Quality of Life Results from the Phase 3 MAESTRO-NASH Trial of Rezdiffra™ (resmetirom)
Patients with MASH/NASH treated with Rezdiffra experienced clinically meaningful and statistically significant improvements in emotional well-being and health distress Study results underscore the positive tolerability profile of Rezdiffra CONSHOHOCKEN, Pa., Sept.…